Brivaracetam may increase exposure to carbamazepine-epoxide (active metabolite); carbamazepine dose reduction should be considered if tolerability issues arise.
Source: NLP:brivaracetam injection
Brand names: Brivaracetam
Epoxide Hydrolase Inhibitors
Route: Intravenous
Contraindications
4 CONTRAINDICATIONS Hypersensitivity to brivaracetam or any of the inactive ingredients in Brivaracetam (bronchospasm and angioedema have occurred) [see Warnings and Precautions (5.4) ] . Hypersensitivity to brivaracetam or any of the inactive ingredients in Brivaracetam. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such as brivaracetam, during pregnancy. Encourage patients who are taking brivaracetam, during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling the toll free number 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/. Risk Summary Available data from the North American Antiepileptic Drug (NAAED) pregnancy registry, a prospective cohort study, case reports, and a case series are insufficient to identify a risk of major birth defects, miscarriage or other maternal or fetal outcomes associated with brivaracetam use during pregnancy. In animal studies, brivaracetam produced evidence of developmental toxicity (increased embryofetal mortality and decreased fetal body weights in rabbits; decreased growth, delayed sexual maturation, and long-term neurobehavioral changes in rat offspring) at maternal plasma exposures greater than clinical exposures [see Data] . The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Oral administration of brivaracetam (0, 150, 300, or 600 mg/kg/day) to pregnant rats during the period of organogenesis did not produce any significant maternal or embryofetal toxicity. The highest dose tested was associated with maternal plasma exposures (AUC) approximately 30 times exposures in humans at the maximum recommended dose (MRD) of 200 mg/day. Oral administration of brivaracetam (0, 30, 60, 120, or 240 mg/kg/day) to pregnant rabbits during the period of organogenesis resulted in embryofetal mortality and decreased f
4 interactions on record
Brivaracetam may increase exposure to carbamazepine-epoxide (active metabolite); carbamazepine dose reduction should be considered if tolerability issues arise.
Source: NLP:brivaracetam injection
Brivaracetam can increase plasma concentrations of phenytoin; phenytoin levels should be monitored when brivaracetam is added or discontinued.
Source: NLP:brivaracetam injection
Rifampin decreases brivaracetam plasma concentrations through CYP2C19 induction, requiring up to 100% dosage increase of brivaracetam.
Source: NLP:brivaracetam injection
Brivaracetam provided no added therapeutic benefit when co-administered with levetiracetam.
Source: NLP:brivaracetam injection